Zydus Lifesciences Eyes $2.5 Billion Ardelyx Buyout, Plans Equity Raise

• Zydus Lifesciences is reportedly exploring a majority stake acquisition in US-based biopharma company Ardelyx Inc. for $2.2–2.5 billion.
• The acquisition would be funded by a Rs 5,000-crore equity raise via QIP and internal cash reserves.
• Ardelyx, listed on Nasdaq with a $1.7 billion market cap, specializes in small-molecule drugs for gastrointestinal and cardio-renal diseases.
• This move aligns with Zydus's strategy to expand into global innovative medicine, diversifying beyond generics.
• Zydus reported strong Q2 FY26 results with revenue up 17% to Rs 6,100 crore and net profit up 38% to Rs 1,260 crore.

Why It Matters: Zydus Lifesciences plans a major US biopharma acquisition to boost global innovative medicine presence.